News – Page 994 – Endpoints News

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

7 years ago

Expanding on their infectious disease deal, Sanofi turns to Evotec for its drug discovery expertise

7 years ago

From mega-round to $172M IPO in weeks, Orchard is bundling cash to back its play on GSK's gene therapy cast-offs

7 years ago

All revved up and ready to roll, Roche is handed the keys to a multibillion-dollar hemophilia market

7 years ago

Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results

7 years ago

Natalie Sacks lands at Harpoon after jumping ship at Aduro; European biotech financings surge

7 years ago

Nimbus chief Don Nicholson hits the exit, handing top job over to Jeb Keiper

7 years ago

J&J hands Arrowhead a plum $3.7B deal for hep B-plus 3 — corralling a possible game-changing RNAi drug

7 years ago

Blackstone bags Clarus, staking out a growing PhIII niche for itself in a rapidly changing biopharma industry

7 years ago

BIO warns members: No more raucous after-hours events — and start putting women in senior posts, now

7 years ago

Roche just heralded a great set of placebo comparisons for their new flu drug — too bad it flopped against generic ...

7 years ago

Sarepta shares yo-yo in the red on another glimpse of stellar results for Duchenne MD gene therapy — what gives?

7 years ago

Three scientists share Nobel for pioneering work on phage display and enzymes; Kite antes up $10M in TCR discovery ...

7 years ago

Forty Seven adds Nobel winner Jim Allison to a dream team of scientific advisers

7 years ago

Genentech takes aim at Biogen and Novartis, highlighting an early look at positive results for their oral SMA drug ...

7 years ago

Citizen petitions: FDA revises guidance to block drugmakers from abusing the system

7 years ago

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma ...

7 years ago

Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic — time to talk launch

7 years ago

UK alarm bells are ringing as a biotech cuts a few trial sites, fretting over Brexit’s impact on drug development

7 years ago

Gurnet Point-backed Boston Pharmaceuticals supercharges pipeline with twin deals grabbing top cast-offs from GSK, ...

7 years ago

Belldegrun and Chang groom their biotech unicorn Allogene for a monster $288M — or so — IPO

7 years ago

Novo Nordisk blueprints new stem cell manufacturing site; Clovis bags a BTD for Rubraca

7 years ago

Eli Lilly steers URLi toward the FDA after scoring positive results in a pair of PhIII diabetes trials

7 years ago

F-Prime's Ben Auspitz co-leads $30M Series A with OrbiMed for his latest rare disease venture

7 years ago

First page Previous page 991 992 993994995 996 997 Next page Last page